Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Japan.
Lung Cancer. 2012 Oct;78(1):100-6. doi: 10.1016/j.lungcan.2012.07.011. Epub 2012 Aug 18.
High expression levels of TrkB and BDNF are associated with aggressive malignant behavior in tumor cells and a poor prognosis in patients with various types of cancer. In this study, we aimed to identify the relationship between TrkB and BDNF expression and clinicopathological variables and prognosis in non-small cell lung cancer (NSCLC). We evaluated TrkB and BDNF expression in the tumor cells of 102 NSCLC patients by immunohistochemistry. Out of all clinicopathological factors examined, only vascular invasion was significantly correlated with TrkB (P=0.010) and BDNF (P=0.015) expression. TrkB-positive tumors had significantly worse disease-free survival (P=0.0094) and overall survival (P=0.0019) than TrkB-negative tumors, and TrkB expression was an independent prognostic factor for disease-free survival (HR 3.735, 95% CI 1.560-11.068, P=0.002) and overall survival (HR 4.335, 95% CI 1.534-15.963, P=0.004) in multivariate analysis. Finally, our analysis revealed that co-expression of TrkB and BDNF conferred poorer prognosis compared with overexpression of either protein alone. Our results indicate that expression of TrkB and BDNF is associated with poor prognosis in NSCLC patients.
高表达水平的 TrkB 和 BDNF 与肿瘤细胞中的侵袭性行为和各种类型癌症患者的不良预后相关。在这项研究中，我们旨在确定 TrkB 和 BDNF 表达与非小细胞肺癌（NSCLC）的临床病理变量和预后之间的关系。我们通过免疫组织化学评估了 102 例 NSCLC 患者肿瘤细胞中的 TrkB 和 BDNF 表达。在所有检查的临床病理因素中，只有血管侵犯与 TrkB（P=0.010）和 BDNF（P=0.015）表达显著相关。TrkB 阳性肿瘤的无病生存率（P=0.0094）和总生存率（P=0.0019）明显低于 TrkB 阴性肿瘤，TrkB 表达是无病生存率（HR 3.735，95%CI 1.560-11.068，P=0.002）和总生存率（HR 4.335，95%CI 1.534-15.963，P=0.004）的独立预后因素。最后，我们的分析表明，TrkB 和 BDNF 的共表达比单独过表达任一蛋白的预后更差。我们的结果表明，TrkB 和 BDNF 的表达与 NSCLC 患者的不良预后相关。
